Co-primary endpoint analysis of HCRN GU 16-257: Phase 2 trial of gemcitabine, cisplatin, plus nivolumab with selective bladder sparing in patients with muscle-invasive bladder cancer (MIBC).

被引：0
|
作者：
Galsky, Matt D.
Daneshmand, Siamak
Lewis, Sara C.
Chan, Kevin G.
Dorff, Tanya B.
Cetnar, Jeremy Paul
Mamtani, Ronac
Kyriakopoulos, Christos
Gogerly-Moragoda, Mahalya
Izadmehr, Sudeh
Yu, Menggang
Zhao, Qianqian
Jun, Tomi
Mehrazin, Reza
Sfakianos, John P.
Pal, Sumanta Monty
机构：
[1] Mt Sinai, Tisch Canc Inst, New York, NY USA
[2] USC, Norris Comprehens Canc Ctr, USC Inst Urol, Los Angeles, CA USA
[3] Icahn Sch Med Mt Sinai, New York, NY USA
[4] City Hope Natl Med Ctr, Duarte, CA USA
[5] City Hope Comprehens Canc Ctr, Dept Med Oncol & Expt Therapeut, Duarte, CA USA
[6] Oregon Hlth & Sci Univ, Portland, OR USA
[7] Univ Penn, Abramson Canc Ctr, Philadelphia, PA USA
[8] Univ Wisconsin, Carbone Canc Ctr, Madison, WI USA
[9] Univ Wisconsin, Madison, WI USA
[10] Sema4, Stamford, CT USA
[11] Icahn Sch Med Mt Sinai, Tisch Canc Inst, New York, NY USA
[12] City Hope Comprehens Canc Ctr, Duarte, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
447
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Bladder-sparing treatment using tislelizumab combined with gemcitabine/cisplatin in selected patients with muscle-invasive bladder cancer: a real-world study
    Luo, Cheng
    Luo, Shuhang
    Wusimanjiang, Wumier
    Wang, Zongren
    Liu, Ping
    Wang, Bin
    Yuan, Dan
    Lin, Hao
    Xu, Abai
    Deng, Nan
    Wu, Kaihui
    Zhu, Xuejin
    Xu, Peng
    Chen, Junxing
    Huang, Bin
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2024, 26 (07): : 1759 - 1767
  • [32] A risk score for the prognosis prediction of the muscle-invasive bladder cancer patients who received gemcitabine plus cisplatin chemotherapy
    Guo, Yupeng
    Dong, Jing
    Ji, Tao
    Li, Xiaoxia
    Rong, Shengzhong
    Guan, Hongjun
    AGING-US, 2022, 14 (23): : 9715 - 9729
  • [33] PrE0807: A phase Ib feasibility trial of neoadjuvant nivolumab (N) without or with lirilumab (L) in cisplatin-ineligible patients (pts) with muscle-invasive bladder cancer (MIBC).
    Grivas, Petros
    Yin, Jun
    Koshkin, Vadim S.
    Cole, Suzanne
    Jain, Rohit K.
    Dreicer, Robert
    Cetnar, Jeremy Paul
    Sundi, Debasish
    Gartrell, Benjamin Adam
    Galsky, Matt D.
    Sievers, Colin M.
    Hahn, Noah M.
    Carducci, Michael Anthony
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [34] PHASE 2 TRIAL OF NEOADJUVANT GEMCITABINE AND CARBOPLATIN FOR MUSCLE-INVASIVE BLADDER CANCER FOLLOWED BY RADICAL CYSTECTOMY
    Koie, Takuya
    Okamoto, Teppei
    Imanishi, Kengo
    Sugiyama, Naoki
    Kudoh, Shigemasa
    Mori, Kazuyuki
    Tachiwada, Tokushi
    Yoneyama, Takahiro
    Hashimoto, Yasuhiro
    Kamimura, Noritaka
    Ohyama, Chikara
    Suzuki, Yuichiro
    JOURNAL OF UROLOGY, 2010, 183 (04): : E657 - E657
  • [35] Phase 1 Trial of Atezolizumab Plus Trimodal Therapy in Patients With Localized Muscle-Invasive Bladder Cancer
    Marcq, Gautier
    Souhami, Luis
    Cury, Fabio L.
    Salimi, Afsar
    Aprikian, Armen
    Tanguay, Simon
    Vanhuyse, Marie
    Rajan, Raghu
    Brimo, Fadi
    Mansure, Jose Joao
    Kassouf, Wassim
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2021, 110 (03): : 738 - 741
  • [36] Neoadjuvant dose-dense gemcitabine and cisplatin (DDGC) in patients (pts) with muscle-invasive bladder cancer (MIBC): Final results of a multicenter phase 11 study.
    Plimack, Elizabeth R.
    Hoffman-Censits, Jean H.
    Kutikov, Alexander
    Greenberg, Richard E.
    Bilusic, Marijo
    Chen, David Y. T.
    Viterbo, Rosalia
    Lallas, Costas D.
    Lin, Jianqing
    Trabulsi, Edouard John
    Geynisman, Daniel M.
    Kelly, William Kevin
    Smaldone, Marc C.
    Devarajan, Karthik
    Adaire-Halenda, Beth
    Cione, Charlotte
    Kilpatrick, Deborah
    Duncan, Gail
    Wong, Yu-Ning
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [37] A phase 2 study of cabozantinib in combination with atezolizumab as neoadjuvant treatment for muscle-invasive bladder cancer (HCRN GU18-343) ABATE study
    Kilari, Deepak
    Szabo, Aniko
    Tripathi, Abhishek
    Paul, Asit K.
    Alter, Robert S.
    Bylow, Kathryn A.
    Nelson, Ariel Ann
    Hall, William A.
    Langenstroer, Peter
    Jacobsohn, Kenneth
    Rini, Brian I.
    Van Veldhuizen, Peter J.
    Johnson, Scott
    Davis, Nancy B.
    Fung, Chunkit
    Milowsky, Matthew I.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [38] Neoadjuvant therapy with camrelizumab plus gemcitabine and cisplatin for patients with muscle-invasive bladder cancer: A multi-center, single-arm, phase 2 study
    Han, Sujun
    Ji, Zhigang
    Jiang, Junhui
    Fan, Xinrong
    Ma, Qi
    Hu, Linjun
    Zhang, Wen
    Ping, Hao
    Wang, Jiansong
    Xu, Wanhai
    Shi, Benkang
    Wang, Wei
    Wang, Haifeng
    Wang, Honglei
    Chen, Shouzhen
    Hu, Hailong
    Guo, Jianming
    Zhang, Shen
    Jiang, Shuai
    Zhou, Quan
    Xing, Nianzeng
    CANCER MEDICINE, 2023, 12 (11): : 12106 - 12117
  • [39] A PHASE 1/2 STUDY OF RAPAMYCIN AND CISPLATIN/GEMCITABINE FOR TREATMENT OF PATIENTS (PTS) WITH MUSCLE-INVASIVE BLADDER CANCER (NCT01938573)
    Makrakis, Dimitrios
    Roudier, Martine
    Wang, Yan
    Vakar-Lopez, Funda
    Garcia, Jose
    Dash, Atreya
    Lin, Daniel
    Schade, George
    Mostaghel, Elahe A.
    Cheng, Heather
    Schweizer, Michael T.
    Holt, Sarah K.
    Gore, John L.
    Yu, Evan
    Lam, Hung-Ming
    Wright, Jonathan L.
    Montgomery, Bruce
    JOURNAL OF UROLOGY, 2022, 207 (05): : E185 - E185
  • [40] A phase 2 study of cabozantinib in combination with atezolizumab as neoadjuvant treatment for muscle-invasive bladder cancer (HCRN GU18-343) ABATE study.
    Kilari, Deepak
    Szabo, Aniko
    Bylow, Kathryn A.
    Alter, Robert S.
    Nelson, Ariel Ann
    Lemke, Emily
    Hall, William Adrian
    Johnson, Scott
    Langenstroer, Peter
    Jacobsohn, Kenneth
    Davis, Nancy B.
    Fung, Chunkit
    Milowsky, Matthew I.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
12345